Asieh Sadat Fattahi - Endoscopic and Minimally Invasive surgery Research Center, Department of surgery, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Ramin Sadeghi - Nuclear Medicine Research Center, Department of nuclear menicine ,Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Abbas Abdollahi - Surgical Oncology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Omid Rohbakhshfar - Endoscopic and Minimally Invasive surgery Research Center, Department of surgery, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Introduction: We evaluate detection rate and local complications of methylene blue (MBD) in comparison of patent blue dye (PBD) for Sentinel Lymph Node (SLN) biopsy in early breast cancer patients. Methods: In a cohort prospective study on 312 patients, divided in two group base on a kind of blue dye, we filled out a check list for the patients with demographic data, size of tumor, stage, detection of sentinel lymph node and complications and then analyzed the data. Results: Mean tumor size was 2.4 cm. Detection rate was in MBD group 77.5% with dye alone and 94.2% with dye and radioisotope; in PBD group it was 80.1% and 92.9% respectively. We had blue discoloration of the skin in 23.7% in PBD group and 14.1% in MBD that was significantly lower and also local inflammation in 1 patient in PBD group and 5 in MBD that was significantly higher. We did not have skin necrosis and systemic. Conclusion: Methylene blue is less expensive and has acceptable detection rate and low complications comparing Patent blue.

Breast cancer, Sentinel lymph node, Blue dye, Local complication